Retatrutide (RT3-GLP) 20mg
Triple agonist (GLP-1/GIP/Glucagon) — higher dose for advanced protocols
In Stock (15 available)
SKU: ML-RETA-20MG
💰 Volume Discounts:
Buy 3+ vials = 10% off · Buy 5+ vials = 15% off
Description
Retatrutide (RT3-GLP) 20mg
Higher dose formulation of Retatrutide, a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors.
Key Benefits
- Triple receptor agonism for comprehensive metabolic support
- Enhanced weight management potential
- Improved insulin sensitivity
- Greater glucagon-mediated fat oxidation
Consult with a healthcare professional for personalized guidance.
Research References
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
A network meta-analysis comparing glucagon receptor agonists including retatrutide on metabolic outcomes across randomized controlled trials.
Retatrutide in type 2 diabetes mellitus and obesity: an overview.
A comprehensive overview of retatrutide's role in treating type 2 diabetes and obesity, covering its mechanism as a triple agonist and clinical trial results.
Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
Preclinical study demonstrating retatrutide's metabolic benefits in animal models of diet-induced obesity and MASH.
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
Comparative study evaluating the efficacy of retatrutide alongside semaglutide and tirzepatide in MC4R-deficient obesity.
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of incretin-based dual and triple agonists including retatrutide for treating overweight and obesity.
Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
Review of multi-target incretin therapies including retatrutide as dual and triple receptor agonists for metabolic disease.
The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
Examines retatrutide as a triple agonist (GLP-1/GIP/glucagon) and its potential to transform obesity and cardiometabolic treatment.
Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.
Systematic review of retatrutide's efficacy and safety in patients with diabetes or obesity and chronic kidney disease.
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
IUPHAR review on repurposing glucagon signaling for obesity and diabetes, covering triple agonists like retatrutide.
Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.
Comprehensive review of FDA-approved and investigational obesity therapies including retatrutide.
Related Products
Retatrutide (RT3-GLP) 10mg
Triple agonist (GLP-1/GIP/Glucagon) for advanced weight management
MOTS-C 40mg
Mitochondrial peptide for metabolic optimization and longevity
Tirzepatide 10mg
Dual GLP-1/GIP receptor agonist for weight management
Tirzepatide 20mg
Dual GLP-1/GIP receptor agonist — higher dose formulation